Condition: Metastatic Pancreatic Adenocarcinoma · Locally Advanced Pancreatic Adenocarcinoma · Sponsor: Medical University of South Carolina
This is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).
This description comes directly from the study's public registry record.
HCC Clinical Trials Office, MD · 843-792-9321 · hcc-clinical-trials@musc.edu
Always discuss trial participation with your own doctor first.
| Hollings Cancer Center at Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| Medical University of South Carolina Hollings Cancer Center | Charleston, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07076212